Navigation Links
Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech

ROCKVILLE, Md., June 2 /PRNewswire/ -- The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and Merck for Best Prophylactic Vaccine.

"This award caps a remarkable period of rapid progress and success in translating Sanaria's whole-organism, sporozoite malaria vaccine candidate from development through cGMP manufacturing and the initiation of clinical trials. It recognizes the remarkable achievements and dedication of the entire Sanaria team and our collaborators," states Stephen L. Hoffman, Sanaria's founder and CEO.

Sanaria's candidate malaria vaccine is composed of live, attenuated parasites. This unique formulation, having satisfied rigorous FDA scrutiny for safety, sterility, purity, potency, and reproducibility of manufacturing, is now undergoing clinical testing in volunteers for safety and efficacy.

About Sanaria Inc. The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include expectations for the effectiveness of a vaccine and its usefulness. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third-parties, clinical trials results, and the ability to commercialize the vaccine.

For further information contact: Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750

SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
2. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
3. USAID Provides Malaria Assistance to Zimbabwe
4. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
5. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
10. Novel Vaccine Approach Offers Hope in Fight Against HIV
11. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... -- --> --> ... das Patent über eine neue Hepatitis-B-Behandlung, welches sie gemeinsam ... Enyo Pharma vergeben haben. Im Rahmen ... von Edelris gemeinsam mit seinen Partnern Inserm und Poxel ... identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die zu ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Beddit® has launched ... Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that rates ... how well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):